Cargando…
Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells
BACKGROUND: Temozolomide (TMZ) is the most commonly used chemotherapeutic agent used to treat glioblastoma (GBM), which causes significant DNA damage to highly proliferative cells. Our observations have added to accumulating evidence that TMZ induces stress-responsive cellular programs known to prom...
Autores principales: | Harder, Bryan G., Peng, Sen, Sereduk, Christopher P., Sodoma, Andrej M., Kitange, Gaspar J., Loftus, Joseph C., Sarkaria, Jann N., Tran, Nhan L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854621/ https://www.ncbi.nlm.nih.gov/pubmed/31726966 http://dx.doi.org/10.1186/s10020-019-0116-z |
Ejemplares similares
-
TRANSLATIONAL RESEARCH-03 MULTIPLE MECHANISMS MODULATE TEMOZOLOMIDE RESISTANCE AND ARE POTENTIAL TARGETS FOR GLIOBLASTOMA THERAPY.
por: Kitange, Gaspar, et al.
Publicado: (2023) -
Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma
por: Daniel, Paul, et al.
Publicado: (2022) -
A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
por: Chen, Xiaoyue, et al.
Publicado: (2018) -
A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours
por: Bowles, D W, et al.
Publicado: (2013) -
Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma
por: Khan, Muhammad Babar, et al.
Publicado: (2021)